Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Advanced Tumors × Capecitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 168 Colorectal Neoplasms 130 Stomach Neoplasms 84 Rectal Neoplasms 82 Pancreatic Neoplasms 66 Neoplasm Metastasis 57 Neoplasms 46 Colonic Neoplasms 36 Esophageal Neoplasms 28 Gallbladder Neoplasms 17 Biliary Tract Neoplasms 16 Bile Duct Neoplasms 16 Carcinoma, Hepatocellular 14 Triple Negative Breast Neoplasms 13 Cholangiocarcinoma 11 Adenocarcinoma 11 Unspecified Adult Solid Tumor, Protocol Specific 10 Adenocarcinoma Of Esophagus 10 Breast Neoplasms, Male 9 Squamous Cell Carcinoma of Head and Neck 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 8 Liver Neoplasms 8 Gastrointestinal Neoplasms 8 Carcinoma, Renal Cell 8 Head and Neck Neoplasms 7 Carcinoma, Non-Small-Cell Lung 7 Prostatic Neoplasms 6 Ovarian Neoplasms 6 Brain Neoplasms 6 Uterine Cervical Neoplasms 5

Interventions

Radiotherapy 1 Nivolumab 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03781362 2022-07-20

Study of CPI-100 in Patients With Advanced Tumors

Coordination Pharmaceuticals, Inc.

Phase 1 Completed

Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡